Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multiple relapses in high-grade osteosarcoma: when to stop aggressive therapy?
Tamamyan G, Dominkus M, Lang S, Diakos C, Mittheisz E, Horcher E, Holter W, Zoubek A, Bielack S, Kager L. Tamamyan G, et al. Among authors: diakos c. Pediatr Blood Cancer. 2015 Mar;62(3):529-30. doi: 10.1002/pbc.25360. Epub 2014 Dec 8. Pediatr Blood Cancer. 2015. PMID: 25611048
Old drug--new insights--better treatment?
Diakos C, Kager L. Diakos C, et al. Leuk Res. 2010 Dec;34(12):1558-9. doi: 10.1016/j.leukres.2010.05.033. Epub 2010 Jul 1. Leuk Res. 2010. PMID: 20594594 No abstract available.
Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold.
Fazekas T, Eickhoff P, Pruckner N, Vollnhofer G, Fischmeister G, Diakos C, Rauch M, Verdianz M, Zoubek A, Gadner H, Lion T. Fazekas T, et al. Among authors: diakos c. BMC Complement Altern Med. 2012 Sep 5;12:147. doi: 10.1186/1472-6882-12-147. BMC Complement Altern Med. 2012. PMID: 22950667 Free PMC article. Clinical Trial.
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
Marth C, Moore RG, Bidziński M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V; ENGOT-en9/LEAP-001 Investigators. Marth C, et al. J Clin Oncol. 2024 Nov 26:JCO2401326. doi: 10.1200/JCO-24-01326. Online ahead of print. J Clin Oncol. 2024. PMID: 39591551
Advancing Global Health Equity in Oncology Clinical Trial Access.
Bloomberg New Economy International Cancer Coalition; McKinsey Cancer Center; Cure4Cancer. Bloomberg New Economy International Cancer Coalition, et al. Cancer Discov. 2024 Dec 2;14(12):2317-2323. doi: 10.1158/2159-8290.CD-24-1288. Cancer Discov. 2024. PMID: 39315831
Metabolic Tumor Volume on 18-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Marker of Survival in Patients With Locally Advanced or Metastatic Neuroendocrine Neoplasms Treated With 177Lutetium-DOTA-Octreotate Peptide Receptor Radionuclide Therapy.
De Silva MK, Chan DLH, Bernard EJ, Conner AJ, Mascall SL, Bailey DL, Roach PJ, Clarke SJ, Diakos CI, Pavlakis N, Schembri G. De Silva MK, et al. Among authors: diakos ci. Pancreas. 2024 Aug 1;53(7):e560-e565. doi: 10.1097/MPA.0000000000002336. Pancreas. 2024. PMID: 38986077
69 results